Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors

Inflammopharmacology

Volumn 16, Issue 1, 2008, Pages 36-39

  Inoue, T ^a,b   Hirata, I ^c   Murano, M ^a,b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Fujita Health University ^*  (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; Cyclooxygenase 2; Dextran sulfate sodium; Dysplasia; Ulcerative colitis

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DEXTRAN SULFATE; NIMESULIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIET; DRUG EFFECT; DYSPLASIA; FEMALE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; COLITIS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; PROSTAGLANDINS G; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TIME FACTORS;

EID: 38949137817     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-006-1543-3     Document Type: Article

References (12)

1. Brazowski, E., Rozen, P., Misonzhnick-Bedny, F., et al. (2005). Characteristics of familial juvenile polyps expressing cyclooxygenase-2, Am J Gastroenterol. 100, 130-8.
2. Cooper, H. S., Murthy, S., Kido, K., et al. (2000). Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation, Carcinogenesis. 21, 757-68.
3. Forrest, K., Symmons, D., Foster, P. (2004). Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther. 20, 1035-43.
4. Miner, P. B. Jr. (1997). Factors influencing the relapse of patients with inflammatory bowel disease, Am J Gastroenterol. 92, 1S-4S.
5. Murthy, S. N., Cooper, H.S., Shim, H., et al. (1993). Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporine, Dig Dis Sci. 38, 1722-34.
6. Okayasu, I., Yamada, M., Mikami, T., et al. (2002). Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model, J Gastroenterol Hepatol. 17, 1078-83.
7. Riddell, R. H., Goldman, H., Ransohoff, D. F., et al. (1983). Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications, Hum Pathol. 14, 931-68.
8. Shinozaki, M., Watanabe, T., Kubota, Y., et al. (2000). High proliferative activity is associated with dysplasia in ulcerative colitis, Dis Colon Rectum. 43, S34-9.
9. Sun, Y., Tang, X. M., Half, E., et al. (2002). Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells, Cancer Res. 62, 6323-8.
10. Tanaka, T., Kohno, H., Suzuki, R., et al. (2003). A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate, Cancer Sci. 94, 965-73.
11. Vetuschi, A., Latella, G., Sferra, R., et al. (2002). Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats, Dig Dis Sci. 47, 1447-57.
12. Yamauchi, T., Watanabe, M., Kubota, T., et al. (2002). Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer, Dis Colon Rectum. 45, 98-103.